The early-stage study will test the drug’s safety, tolerability and biological effects in humans
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
Originally established in Punjab, the Vasculitis Society of India is now expanding its footprint nationwide
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Subscribe To Our Newsletter & Stay Updated
